References
  1. Munshi N MM, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a Claims Database to Characterize and Estimate the Incidence Rate for Castleman Disease. Leuk Lymphoma 2015;56(5):1252-1260.
  2. Casper C. The Aetiology and Management of Castleman Disease at 50 Years: Translating Pathophysiology to Patient Care Br J Haematol 2005;129: 3 – 17
  3. Carbone A, Borok M, Damania B, et al. Castleman disease. Nat Rev Dis Primers 2021;7:84.
  4. Sopfe J, Endres A, Campbell K, et al. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Pediatr Blood Cancer 2019;66:e27613.
  5. Bjarnason I, Cotes PM, Knowles S, Reid C, Wilkins R, Peters TJ. Giant lymph node hyperplasia (Castleman’s disease) of the mesentery. Observations on the associated anemia. Gastroenterology 1984;87:216-23.
  6. Kalayoğlu Beşışık S, Yönal Hindilerden İ, Hindilerden F, Doğan İ, Beşışık F. A Rare Cause of Unexplained Refractory Iron Deficiency Anemia: Unicentric Plasma-Cell Type Castleman’s Disease. Turk J Haematol 2016;33:257-8.
  7. Parez N, Bader-Meunier, B., Roy, C. et al. Paediatric Castleman disease: report of seven cases and review of the literature. European Journal of Pediatrics 1999;158, 631–637.